Top 10 Companies in the Global Pharmaceutical Grade Microcrystalline Cellulose Market (2026): Market Leaders Powering Global Pharmaceutical Excipients

MARKET INSIGHTS

Global pharmaceutical grade microcrystalline cellulose market size was valued at USD 723.4 million in 2024. The market is projected to grow from USD 775.6 million in 2025 to USD 1,299.02 million by 2032, exhibiting a CAGR of 7.3% during the forecast period.

Pharmaceutical grade microcrystalline cellulose (MCC) is a purified, partially depolymerized cellulose produced through acid hydrolysis of alpha-cellulose obtained from wood pulp or cotton fibers. It serves as a crucial excipient in drug formulations due to its excellent binding, disintegration, and compressibility properties, making it indispensable in tablet manufacturing. The product exists in various grades differentiated by particle size and density, with common types including PH-101, PH-102, and PH-200.

The market growth is driven by increasing pharmaceutical production, particularly in emerging economies, and rising demand for direct compression technology in tablet manufacturing. Furthermore, the expanding generic drug market and advancements in modified‑release formulations are creating new opportunities. Key players like DuPont, JRS Pharma, and Roquette are investing in capacity expansions to meet growing demand. For instance, in Q1 2024, DuPont announced a USD 50 million investment to expand its MCC production capacity in the U.S., anticipating sustained market growth through 2030.

Global Pharmaceutical Grade Microcrystalline Cellulose Market – View in Detailed Research Report

---

🔟 1. DuPont Corporation

Headquarters: Wilmington, Delaware, USA
Key Offering: Pharmaceutical grade MCC (PH-101, PH-102, PH-200)

DuPont is a global leader in excipient solutions, leveraging its deep expertise in material science to supply high‑quality MCC to pharmaceutical manufacturers worldwide. In 2024, DuPont expanded its U.S. production capacity by USD 50 million, reinforcing its commitment to meeting the growing demand for direct compression tablets.

Sustainability & Growth Initiatives:

• Investment in sustainable wood pulp sourcing and closed‑loop water systems
• Carbon‑neutral manufacturing targets by 2035
• Strategic partnerships with leading pharma companies for joint R&D

---

9️⃣ 2. JRS Pharma

Headquarters: Düsseldorf, Germany
Key Offering: High‑purity MCC grades for tablet and capsule formulations

JRS Pharma focuses on delivering premium MCC with stringent compliance to USP, EP, and JP standards. The company has recently increased its R&D budget to develop co‑processed excipients that enhance flowability and compressibility.

Sustainability & Growth Initiatives:

• Water recycling and energy‑efficient production lines
• Certification of all facilities under ISO 14001
• Expansion into emerging markets in Asia‑Pacific

---

8️⃣ 3. Roquette

Headquarters: Roquette, France
Key Offering: Wide range of MCC grades including specialty and high‑purity variants

Roquette is renowned for its advanced functional MCC grades that support controlled‑release and orally disintegrating tablets. The company continues to invest in technology to reduce moisture content and improve particle size distribution.

Sustainability & Growth Initiatives:

• Use of renewable raw materials from sustainable forestry
• Reduction of CO₂ emissions by 25% over the next decade
• Collaborations with academic institutions for process innovation

---

7️⃣ 4. Asahi Kasei

Headquarters: Tokyo, Japan
Key Offering: MCC for tablet manufacturing and nutraceutical applications

Asahi Kasei serves the Asia‑Pacific market with cost‑effective MCC solutions, emphasizing high purity and consistent particle size. The company is expanding its manufacturing footprint in China and India.

Sustainability & Growth Initiatives:

• Low‑energy purification processes
• Commitment to zero waste in production facilities
• Community engagement programs in local sourcing regions

---

6️⃣ 5. Mingtai

Headquarters: Guangzhou, China
Key Offering: Cost‑effective MCC for generic drug manufacturers

Mingtai supplies high‑quality MCC to the rapidly growing Chinese generic drug sector. The company has recently upgraded its plant to meet GMP standards and expand production capacity.

Sustainability & Growth Initiatives:

• Utilization of locally sourced wood pulp to reduce transportation emissions
• Implementation of water‑saving technologies
• Strategic alliances with regional pharma companies

---

5️⃣ 6. Accent Microcell

Headquarters: Bangalore, India
Key Offering: Specialty MCC grades for tablet and capsule formulations

Accent Microcell focuses on providing tailored MCC solutions to the Indian market, emphasizing compliance with international pharmacopeial standards.

Sustainability & Growth Initiatives:

• Adoption of renewable energy in manufacturing
• Waste‑to‑energy conversion projects
• Local community development programs

---

4️⃣ 7. Sigachi

Headquarters: Mumbai, India
Key Offering: High‑purity MCC for nutraceutical and cosmeceutical applications

Sigachi supplies MCC that meets stringent purity requirements for nutraceuticals and cosmeceuticals, supporting the growing demand for high‑quality excipients in these sectors.

Sustainability & Growth Initiatives:

• Use of sustainably sourced cotton fibers
• Water reclamation systems
• Partnerships with global health organizations

---

3️⃣ 8. Wei Ming Pharmaceutical

Headquarters: Taipei, Taiwan
Key Offering: MCC for nutraceutical and over‑the‑counter products

Wei Ming Pharmaceutical expands its portfolio to include MCC for nutraceuticals, leveraging its strong distribution network in East Asia.

Sustainability & Growth Initiatives:

• Energy‑efficient production lines
• Zero‑water‑usage certification
• Investment in local community health programs

---

2️⃣ 9. Anhui Sunhere Pharmaceutical

Headquarters: Hefei, Anhui, China
Key Offering: MCC for tablet manufacturing in the domestic market

Anhui Sunhere focuses on supplying high‑quality MCC to Chinese pharmaceutical manufacturers, emphasizing strict GMP compliance.

Sustainability & Growth Initiatives:

• Use of locally sourced raw materials
• Carbon‑neutral production targets
• Collaboration with local universities for process innovation

---

1️⃣ 10. Shandong Guangda

Headquarters: Shandong, China
Key Offering: MCC for generic drug production

Shandong Guangda supplies MCC to the growing generic drug market in China, focusing on cost‑effective production while maintaining high quality.

Sustainability & Growth Initiatives:

• Implementation of waste‑reduction protocols
• Energy‑saving technologies in the plant
• Strategic partnerships with regional pharma manufacturers

---

Download FREE Sample Report

Global Pharmaceutical Grade Microcrystalline Cellulose Market – View in Detailed Research Report

Get Full Report

Global Pharmaceutical Grade Microcrystalline Cellulose Market – View in Detailed Research Report

---

Outlook: The Future of MCC Market

The Global Pharmaceutical Grade Microcrystalline Cellulose Market is projected to exhibit strong growth, with its size estimated to increase from USD 775.6 million in 2025 to approximately USD 1,299.02 million by 2034, representing a compound annual growth rate of 7.30%. This expansion is primarily fueled by the indispensable role of MCC as a binder, disintegrant, and diluent in solid dosage formulations, particularly tablets, which continue to be the most prevalent form of drug delivery worldwide.

Key Trends Shaping the Market:

• Rapid capacity expansions by leading players such as DuPont and JRS Pharma to meet growing demand.
• Regulatory push for stricter compliance with USP, EP, and JP standards.
• Increasing adoption of advanced functional MCC grades for controlled‑release and orally disintegrating tablets.
• Growth in nutraceutical and cosmeceutical markets requiring pharmaceutical‑grade excipients.
• Strategic partnerships and backward integration to secure raw material supply chains.

Future Trends

As the pharmaceutical industry shifts towards biologics and high‑potency active ingredients, MCC’s role as a stable, inert carrier will become increasingly critical in lyophilized products and precise dosing applications. The market will also see a rise in co‑processed excipients that combine MCC with other agents to improve flowability and compressibility, opening new avenues for high‑value drug delivery systems.